| Theme | Diversified Modalities of Liver Metastasis Treatment | |
|---|---|---|
| Title | Adjuvant Chemotherapyafter Resection of Liver Metastases Resulting from Colorectal Cancer | |
| Publish Date | 2011/04 | |
| Author | Kuniharu Yamamoto | Department of Surgery, Yamagata Prefectural Central Hospital / Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Tohoku University Graduate School of Medicine |
| Author | Yu Katayose | Division of Integrated Surgery and Oncology, Tohoku University Graduate School of Medicine / Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Tohoku University Graduate School of Medicine |
| Author | Kei Nakagawa | Division of Integrated Surgery and Oncology, Tohoku University Graduate School of Medicine / Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Tohoku University Graduate School of Medicine |
| Author | Michiaki Unno | Division of Integrated Surgery and Oncology, Tohoku University Graduate School of Medicine / Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Tohoku University Graduate School of Medicine |
| [ Summary ] | Hepatic resection is the only potentially curative treatment for patients having colorectal cancer with liver metastases. However, tumor relapses occur at high rates in patients who have undergone liver resection. Presently, no clinical study has demonstrated any survival benefits for patients treated with adjuvant therapies (hepatic arterial infusion and/or systemic chemotherapy). In this paper, we review randomized clinical trials from medical literature. We also present some findings from a multicenter phase II study (Miyagi HBPCOG-001) employing modified FOLFOX6 as an adjuvant treatment after liver metastases resection for colorectal cancer. | |